



OXB's Competitive Edge: Driving future delivery through innovation

Dr. Kyriacos Mitrophanous
Chief Innovation Officer

Legal disclaimer


This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc (“OXB” or the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and may depend on a number of factors.



Innovation plays a pivotal role in the success of a CDMO

OXB has unique innovation capabilities to differentiate, protect and build our market position



Why is Innovation critical to a CDMO?

- Technology is still developing
- Regulatory requirements are evolving
- Clients' needs are more sophisticated
- Enabling new modalities

OXB client-centric innovation

Our innovation generates multiple tangible benefits for our clients...



... enabling us to provide best-in-class services across clients' key selection criteria


	LV	AAV
Titre	10 ⁹ TU/mL	10 ¹⁵ vg/L
Speed	9 months	7 months
Pricing	Competitive	Competitive
Robustness	Top tier	Top tier
Quality	Best in class	Best in class

Best in class Top tier Competitive



OXB platforms are supported by cutting-edge technologies

Platform performance driven by internally developed innovations



Key trends shaping the future of cell and gene therapy

Breakthroughs in vector engineering, automation, and new therapeutic modalities



AI and automation

Understand processes, replace manual steps, reduce variability and improve scalability



Next generation platforms AAV – targeted AAV vectors

Engineered capsids for superior safety and efficacy



Next generation platforms LV – LV for *in vivo* CAR-T

Broader patient access



New modalities such as non-viral vectors (e.g. LNPs)

Enabling new modalities in CGT

Leveraging digital tools to enhance operational delivery

Advanced digital tools are redefining how we work and deliver client value



Digitising lab analysis - to accelerate decision-making

Replaces manual Excel workflows with advanced analytics, modelling, and real-time dashboards



Predicting scale-up performance - to derisk development and accelerate timeline

Uses dynamic, causal models to predict titre, residuals, and cell metabolism during scale-up



Enhancing process robustness - through real-time monitoring and traceability

Continuously records lab conditions, automated liquid handling activity, and temperature-controlled storage with real-time alerts



Integrating enterprise data - to enable faster, better decisions

Secure, near real-time access to OXB data through governed platforms and automated APIs — eliminating data silos



OXB Operational impact

Drive efficiency and support OXB's growth

- Higher operational efficiency and scalability
- Reduced errors, deviations, and downtime
- Stronger process understanding
- Faster and better-informed decision-making

Client Benefits

Deliver tangible benefits to our clients

- Faster programme delivery
- Lower development and manufacturing risk
- Greater transparency and confidence
- Stronger regulatory and quality assurance


Notes: * IDMO – Integrated Development Manufacturing Organisation; AMT – Advanced Manufacturing Technology

Sources: OmniaBio press release (2024); Samsung Biologics – AI implementation to enhance quality whitepaper (2024); Lonza press release (2024 & 2025); Samsung Biologics – Enabling digital twins with computational fluid dynamics modelling (2025); Cellares press release (2025)

Expanding our offering to unlock *in vivo* cell therapies

Our technologies provide a unique opportunity to become a leader in this fast-growing field

Critical elements for *in vivo* CAR-T programs:




OXB existing technologies and experience to position as market leader





Attractive market opportunity for *in vivo* cell therapies

74% of trials are pure CAR-T; LV and LNPs are the main vectors used with most trials at discovery and pre-clinical phases

In vivo cell therapy drug candidates on trials by approach⁽¹⁾
 From discovery to pre-registration phase, Viral & Non-viral, Q1 2026



In vivo cell therapy drug candidates on trials by vector
 From discovery to pre-registration phase, Viral & Non-viral, Q1 2026



(1) CAR-T, CAR-NK, TCR, CAR-M are immune cell-based therapies, rest are non-immune (e.g. Stem cell)

(2) Highest development stage among all indications and geographies is shown

Source: GlobalData extract as of Apr'26, in vivo engineered cells are mapped out based on open sources and include only disclosed in vivo drug candidates



Exploring the potential of non-viral delivery platforms

We acknowledge market evolution and technology maturation and have transferable capabilities

Pipeline & industry shift

- **Rapid growth** of non-viral, especially *in vivo*
- **Clients building multi-platform viral/non-viral** strategies
- **CDMO selection criteria can include non-viral** capabilities

Technology potential

- **Promise in overcoming certain viral vector limitations**, incl. scalability, re-dosability, payload flexibility
- Non-viral (LNPs) could enable shift from bespoke solutions toward **industrialised, repeatable delivery**

Strategic timing

- Non-viral technologies are increasingly **clinically validated**, but supply landscape is **not yet consolidated** in some segments



OXB Capabilities

- Experience with Viral Like Particles
- GMP facilities and quality systems in place
- Transferable expertise spanning manufacture and analytics
- Existing fill & finish capabilities and infrastructure

Opportunities for OXB

- Enter new markets
- Protect revenue
- De-risk cannibalisation
- Secure new partnerships

Why we are best placed to stay ahead


OXB innovation will drive differentiation and accelerate clients' success

Established innovation processes & governance ●

Culture of scientific excellence & problem solving ●

Unrivalled track record in innovation ●

Strong intellectual property position backed by deep technical expertise ●



Let's deliver life-changing therapies together

A global quality and innovation-led
CDMO in cell and gene therapy

[OXB.com](https://www.oxb.com)

